Kayla Campbell, OD
Optometrist · Barboursville, WVNPI 1306253166
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,529 of the $15,641 with a category attached, or 60.9%. 27 manufacturers reported payments, led by Pfizer at 30.8% of the total. 2025 is the largest year on record at $6,606, 6.3 times the $1,041 reported in 2019. Among optometrist clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $49.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Bausch & Lomb Americas Inc.$2K
- Eyevance Pharmaceuticals LLC$2K
- Alcon$1K
- Sun Pharmaceutical Industries Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$632
- plus $3K from 21 others
What the payments were for
- Consulting fees$4,72530%
- Speaking & faculty fees$1,2008%
- Food & beverage$9,52961%
- Education$791%
- Entertainment$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $4,823 |
| Bausch & Lomb Americas Inc. | 71 | $2,343 |
| Eyevance Pharmaceuticals LLC | 17 | $1,755 |
| Alcon | 49 | $1,491 |
| Sun Pharmaceutical Industries Inc. | 64 | $1,438 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $632 |
| Johnson & Johnson Vision Care, Inc. | 16 | $561 |
| AbbVie(2 entities) | 18 | $488 |
| Dompe US, Inc. | 5 | $297 |
| LKC Technologies, Inc. | 4 | $241 |
| Tarsus Pharmaceuticals, Inc. | 9 | $225 |
| Topcon Healthcare, Inc. | 2 | $208 |
| Novartis | 9 | $184 |
| Oyster Point Pharma, Inc. | 8 | $178 |
| Coopervision Inc. | 2 | $145 |
| Genmab U.S., Inc. | 1 | $125 |
| Optos, Inc. | 2 | $108 |
| Boehringer Ingelheim | 1 | $104 |
| Seagen Inc. | 1 | $79 |
| Shire North American Group Inc | 4 | $67 |
| Kala Pharmaceuticals, Inc. | 2 | $29 |
| Thea Pharma Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Harrow Eye, LLC | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$4,850
- Zerviate$1,304
- INFUSE$747
- TOTAL30$271
- Oxervate$248
- CEQUA$247
- Acuvue$225
- Flarex$161
- DAILIES TOTAL1$137
- Tobradex ST$133
- DAILIES$132
- XIIDRA$121
- MIEBO$121
- BIOTRUE ONE DAY$116
- RESTASIS MULTIDOSE$114
- MyDay Contact Lens$112
- Precision 1$111
How this compares
$15,641 in reported general payments places this provider in the 95th percentile of 210 optometrist providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 89 | $142,732 |
| XiidraLifitegrast | 25 | $47,005 |
| CequaCyclosporine | 27 | $26,936 |
| Cyclosporine | 13 | $10,627 |
| TyrvayaVarenicline Tartrate | 16 | $10,611 |
| LumiganBimatoprost | 15 | $8,942 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $5,434 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $4,760 |
| Loteprednol Etabonate | 14 | $2,541 |
| Prednisolone Acetate | 25 | $1,372 |
| Latanoprost | 54 | $903 |
| Brimonidine Tartrate | 21 | $873 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 12 | $701 |
| Timolol Maleate | 49 | $503 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 27 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $488 | $157,107122 claims |
| Bausch & Lomb Americas Inc.Xiidra | $2,343 | $47,00525 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,438 | $26,93627 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $178 | $10,61116 claims |
| AlconSimbrinza | $1,491 | $4,76024 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $632 | $2,54114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 optometrist providers in West Virginia.
Other optometrist in Barboursville
- Bryce PeekBarboursville$8K
- Melissa LeoniBarboursville$6K
- Gregory MooreBuckhannon$28K
- Steven PotwinSaint Albans$24K
- Lee MooreCharles Town$10K
- Jill ShowalterVienna$10K
- James FickClarksburg$8K
- Laura Suppa SammonsCharleston$8K
- Mark WhittingtonCharleston$8K
- Hobart SeeseMorgantown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.